Q3 2026 – GreyKeel represented Bayern Kapital and b2venture, as co-lead investors, in connection with the preferred stock financing of an early-stage biotechnology company.
Q3 2026 – GreyKeel represented Atlantica Ventures, an early-stage venture capital fund, in connection with its participation in the Series B financing of a supply chain technology company.
Q3 2026 – GreyKeel represented a private sports technology company in connection with its formation and organizational matters.
Q3 2026 – GreyKeel represented Precision Digital Health, a healthtech company focused on data integration and analytics, in connection with its Series Seed financing.
Q3 2026 – GreyKeel represented Sendmarc, an international cybersecurity company, in connection with its convertible note financing.
Q2 2026 – GreyKeel represented a private biotechnology company in connection with its acquisition of an exclusive license to a patent portfolio.
Q2 2026 – GreyKeel represented a private technology company in connection with a “flip” transaction with its foreign affiliate.
Q2 2026 – GreyKeel represented b2venture, a European venture capital firm, in connection with a round of venture capital financing for an e-commerce company. b2venture was the lead investor in the transaction.
Q1 2026 – GreyKeel represented a European family office in connection with it leading the Series A financing for a U.S. biotechnology company.
Q1 2026 – GreyKeel represented Nula Therapeutics, a biotechnology company developing medicines targeting the nuclear envelope, in connection with its acquisition via merger of an early-stage biotechnology company.
Q1 2026 – GreyKeel advised Nula Therapeutics, a biotechnology company developing medicines targeting the nuclear envelope, in connection with its $20 million award from the U.S. Advanced Research Projects Agency for Health (ARPA-H).
Q1 2026 – GreyKeel represented FluentLogic, a data infrastructure company, in connection with its organizational matters and fund-raising initiatives.
Q1 2026 – GreyKeel represented Apollo Health Ventures, a transatlantic venture capital firm, in connection with its participation in the Series C financing of a late clinical-stage neurotechnology company.
Q4 2025 – GreyKeel represented Thymofox, a biotechnology company developing targeted, orally available medicines for thymus regeneration, in connection with a convertible note financing.
Q4 2025 – GreyKeel represented Boston Millennia Partners, a venture capital firm, in connection with its participation in the Series Seed financing of a healthtech company.
Q4 2025 – GreyKeel represented Nula Therapeutics, a biotechnology company developing medicines targeting the nuclear envelope, in connection with its Series Seed financing.
Q4 2025 – GreyKeel represented Telos Biotech, a company developing technology to enhance the next generation of cell therapies, in connection with its Series Seed financing.
Q4 2025 – GreyKeel represented a private biotechnology client in connection with its convertible note financing.
Q4 2025 – GreyKeel represented a family office client in connection with the partial sale of its interest in a private aircraft.
Q4 2025 – GreyKeel represented Precision Digital Health, a healthtech company focused on data integration and analytics, in connection with a convertible note financing.
Q3 2025 – GreyKeel represented b2venture, a European venture capital firm, in connection with the Series Seed financing of a company developing a digital operations platform for motorsport teams. b2venture was the lead investor in the transaction.
Q3 2025 – GreyKeel represented Boston Millennia Partners, a venture capital firm, in connection with the convertible note financing of a health-data analytics company.